Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology

2016 ◽  
Vol 12 (1) ◽  
pp. 84-98 ◽  
Author(s):  
Jianing Meng ◽  
Vivek Agrahari ◽  
Ibrahima Youm
Keyword(s):  
Drug Delivery ◽  
Central Nervous System ◽  
Nervous System ◽  
Targeted Drug Delivery ◽  
Central Nervous System Tumors ◽  
Nervous System Tumors ◽  
The Central Nervous System ◽  
Targeted Drug

scholarly journals Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems

2020 ◽  
Vol 18 ◽  
Author(s):  
Vimal Patel ◽  
Vishal Chavda ◽  
Jigar Shah
Keyword(s):  
Drug Delivery ◽  
Central Nervous System ◽  
Nervous System ◽  
Targeted Drug Delivery ◽  
Drug Dose ◽  
The Body ◽  
Brain Drug Delivery ◽  
The Central Nervous System ◽  
Targeted Drug ◽  
The Brain

: Neurology and associated nanotherapeutics is a complex field in terms of therapeutics and neurological disorder complexity. Brain is an intricate appendage and requires more precise embattled treatment for the particular diseases and hence it’s a broad scale for developing more targeted drug deliveries. The brain is one of the most inaccessible tissues of the body due to the existence of the blood-brain barrier (BBB), thus delivery of drugs inside the brain is a striking dare and it is also tricky to treat central nervous system (CNS) complications pharmacologically. The therapeutic aspiration is to accomplish a lowest drug meditation in the brain tissues so as to gain favoured therapeutic results. To devastate this obstacle, nanotechnology is engaged in the field of targeted brain drug delivery and neuropathology targeting. These carriers hold myriad ability as they may augment the drug delivery into the brain by shielding them from degradation and prolonging their transmission in the blood, as well as promoting their transport through the BBB. Nanopharmaceuticals are quickly sprouting as new avenue that is engaged with the drug-loaded nanocarriers to demonstrate unique physicochemical properties and tiny size range for penetrating into the central nervous system. The enchantment behind their therapeutic achievement is the condensed drug dose and inferior toxicity, whereby restricting the therapeutic compound to the specific site. Therefore, in this article we have tried to recapitulate the advances the novel scopes for the brain targeted drug delivery for complex neurological disorders.

scholarly journals Epidemiologic Study of Central Nervous System Tumors in Rwanda

2020 ◽  
pp. 1-14
Author(s):  
David Hakizimana ◽  
Agabe Emmy Nkusi ◽  
David Hakizimana ◽  
Eric Shingiro ◽  
Paulin Munyemana ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Brain Tumors ◽  
Age Groups ◽  
Epidemiologic Study ◽  
Cns Tumors ◽  
Central Nervous System Tumors ◽  
Secondary Neoplasms ◽  
Nervous System Tumors ◽  
The Central Nervous System

Introduction: Tumors of the central nervous system (CNS) are primary or secondary neoplasms located within the craniovertebral cavity. The incidence of CNS tumors is not uniform with variation between different countries, age groups and races. Objective: Our study aim was to generate new knowledge of the epidemiology of central nervous system tumors in Rwanda. Method: This was an observational retrospective study of all patients diagnosed with CNS tumors in Rwanda over a period of 10 years, from 1st January 2006 to 31st December 2015. Results: 466 patients enrolled, (52.2% females, 47.8% males). The median age at diagnosis of was 37 years. Brain tumors were 82.7%; spine tumor patients were 16.4%. The average annual age-standardized incidence of CNS tumors was 0.43/100, 0000 person-years and varied with age groups. Tumors of meningothelial cells represented the majority of brain tumors (31.8%). Metastatic tumors were the far most common spine tumors category. 55.8 % of CNS tumors reported in our study were histologically confirmed and of nonmalignant meningiomas were the commonest (33.9%). Conclusion: This is the very first study done on epidemiology of CNS tumors in Rwanda, and generated data about incidence of CNS tumors in Rwanda and their location and histological distribution.

Low-grade central nervous system tumors

2002 ◽  
Vol 12 (2) ◽  
pp. 1-4 ◽  
Author(s):  
M. Beatriz S. Lopes ◽  
Edward R. Laws
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Brain Tumors ◽  
Diagnostic Procedures ◽  
Central Nervous System Tumors ◽  
Low Grade ◽  
Pathological Features ◽  
Nervous System Tumors ◽  
Pathological Classification ◽  
The Central Nervous System

Low-grade tumors of the central nervous system constitute 15 to 35% of primary brain tumors. Although this category of tumors encompasses a number of different well-characterized entities, low-grade tumors constitute every tumor not obviously malignant at initial diagnosis. In this brief review, the authors discuss the pathological classification, diagnostic procedures, treatment, and possible pathogenic mechanisms of these tumors. Emphasis is given in the neu-roradiological and pathological features of the several entities.

scholarly journals Primary Cilia–Related Pathways Moderate the Development and Therapy Resistance of Glioblastoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Minghao Li ◽  
Jiaxun Zhang ◽  
Haonan Zhou ◽  
Rong Xiang
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Primary Cilia ◽  
Therapy Resistance ◽  
Central Nervous System Tumors ◽  
Degenerative Diseases ◽  
Nervous System Tumors ◽  
The Central Nervous System ◽  
G2 Phase ◽  
Abnormal Cilia

As microtubule-based structures, primary cilia are typically present on the cells during the G0 or G1-S/G2 phase of the cell cycle and are closely related to the development of the central nervous system. The presence or absence of this special organelle may regulate the central nervous system tumorigenesis (e.g., glioblastoma) and several degenerative diseases. Additionally, the development of primary cilia can be regulated by several pathways. Conversely, primary cilia are able to regulate a few signaling transduction pathways. Therefore, development of the central nervous system tumors in conjunction with abnormal cilia can be regulated by up- or downregulation of the pathways related to cilia and ciliogenesis. Here, we review some pathways related to ciliogenesis and tumorigenesis, aiming to provide a potential target for developing new therapies at genetic and molecular levels.

Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies

2020 ◽  
Vol 20 (30) ◽  
pp. 2762-2776
Author(s):  
Xin Zhao ◽  
Yun Ye ◽  
Shuyu Ge ◽  
Pingping Sun ◽  
Ping Yu
Keyword(s):  
Drug Delivery ◽  
Central Nervous System ◽  
Nervous System ◽  
Anticancer Drugs ◽  
Targeted Drug Delivery ◽  
Targeted Delivery ◽  
Cytotoxic Agents ◽  
Cns Tumors ◽  
Blood Brain ◽  
Targeted Drug

Central nervous system (CNS) cancers are among the most common and treatment-resistant diseases. The main reason for the low treatment efficiency of the disorders is the barriers against targeted delivery of anticancer agents to the site of interest, including the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB). BBB is a strong biological barrier separating circulating blood from brain extracellular fluid that selectively and actively prevents cytotoxic agents and majority of anticancer drugs from entering the brain. BBB and BBTB are the major impediments against targeted drug delivery into CNS tumors. Nanotechnology and its allied modalities offer interesting and effective delivery strategies to transport drugs across BBB to reach brain tissue. Integrating anticancer drugs into different nanocarriers improves the delivery performance of the resultant compounds across BBB. Surface engineering of nanovehicles using specific ligands, antibodies and proteins enhances the BBB crossing efficacy as well as selective and specific targeting to the target cancerous tissues in CNS tumors. Multifunctional nanoparticles (NPs) have brought revolutionary advances in targeted drug delivery to brain tumors. This study reviews the main anatomical, physiological and biological features of BBB and BBTB in drug delivery and the recent advances in targeting strategies in NPs-based drug delivery for CNS tumors. Moreover, we discuss advances in using specific ligands, antibodies, and surface proteins for designing and engineering of nanocarriers for targeted delivery of anticancer drugs to CNS tumors. Finally, the current clinical applications and the perspectives in the targeted delivery of therapeutic molecules and genes to CNS tumors are discussed.

Sign in / Sign up

Export Citation Format

Share Document